関連ニュース

Ten stocks worth more than $2 billion each have more than a third of their float sold short. At the top of the list, one company has more than 80% of its float sold short.

Recursion Pharmaceuticals NASDAQ: RXRX outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley's Global Healthcare Conference, with CEO and President Najat Khan emphasizing

Recursion Pharmaceuticals NASDAQ: RXRX is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and suppor

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and S